Literature DB >> 12753745

HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis.

Franck Dequiedt1, Herbert Kasler, Wolfgang Fischle, Veronique Kiermer, Marc Weinstein, Brian G Herndier, Eric Verdin.   

Abstract

We report that HDAC7, a class II histone deacetylase, is highly expressed in CD4(+)CD8(+) double-positive thymocytes. HDAC7 inhibits the expression of Nur77, an orphan receptor involved in apoptosis and negative selection, via the transcription factor MEF2D. HDAC7 is exported from the nucleus during T cell receptor activation, leading to Nur77 expression. A triple HDAC7 mutant (S155A, S318A, S448A) is not exported from the nucleus in response to TCR activation and suppresses TCR-mediated apoptosis. Conversely, a fusion of HDAC7 to the transcriptional activator VP16 activates Nur77 expression. Inhibition of HDAC7 expression by RNA interference causes increased apoptosis in response to TCR activation. These observations define HDAC7 as a regulator of Nur77 and apoptosis in developing thymocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753745     DOI: 10.1016/s1074-7613(03)00109-2

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  81 in total

1.  Expression of Twist2 is controlled by T-cell receptor signaling and determines the survival and death of thymocytes.

Authors:  S Oh; J Oh; C Lee; S Oh; S Jeon; J Choi; S Hwang; Y Lee; H Lee; R H Seong
Journal:  Cell Death Differ       Date:  2016-07-08       Impact factor: 15.828

2.  An expression screen reveals modulators of class II histone deacetylase phosphorylation.

Authors:  Shurong Chang; Svetlana Bezprozvannaya; Shijie Li; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-27       Impact factor: 11.205

Review 3.  Class II histone deacetylases: from sequence to function, regulation, and clinical implication.

Authors:  Xiang-Jiao Yang; Serge Grégoire
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

4.  Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors.

Authors:  Serge Grégoire; Xiang-Jiao Yang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner.

Authors:  Eric D Jensen; Tania M Schroeder; Jaclyn Bailey; Rajaram Gopalakrishnan; Jennifer J Westendorf
Journal:  J Bone Miner Res       Date:  2008-03       Impact factor: 6.741

6.  Specific activity of class II histone deacetylases in human breast cancer cells.

Authors:  Vanessa Duong; Caroline Bret; Lucia Altucci; Antonello Mai; Céline Duraffourd; Julie Loubersac; Pierre-Olivier Harmand; Sandrine Bonnet; Sergio Valente; Thierry Maudelonde; Vincent Cavailles; Nathalie Boulle
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.

Authors:  Eros Di Giorgio; Andrea Clocchiatti; Sara Piccinin; Andrea Sgorbissa; Giulia Viviani; Paolo Peruzzo; Salvatore Romeo; Sabrina Rossi; Angelo Paolo Dei Tos; Roberta Maestro; Claudio Brancolini
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

8.  Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes.

Authors:  Herbert G Kasler; Eric Verdin
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

9.  Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function.

Authors:  Fiona L Scott; Greg J Fuchs; Sarah E Boyd; Jean-Bernard Denault; Christine J Hawkins; Franck Dequiedt; Guy S Salvesen
Journal:  J Biol Chem       Date:  2008-05-05       Impact factor: 5.157

Review 10.  Role of diacylglycerol kinases in T cell development and function.

Authors:  Sruti Krishna; Xiaoping Zhong
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.